Hypopituitarism Overview
Hypopituitarism is a life-threatening endocrine disorder requiring immediate recognition and hormone replacement to prevent excess mortality, particularly from adrenal crisis, cardiovascular disease, and malignancies. 1
Definition and Epidemiology
Hypopituitarism represents complete or partial deficiency of one or more pituitary hormones, including:
- ACTH (causing central adrenal insufficiency)
- TSH (causing central hypothyroidism)
- LH/FSH (causing central hypogonadism)
- Growth hormone (causing GH deficiency)
- ADH/vasopressin (causing diabetes insipidus - though this can occur independently)
The prevalence is approximately 45 cases per 100,000 with an incidence of 4 cases per 100,000 per year, though this is likely underestimated 1. Central adrenal insufficiency alone affects 150-280 per million inhabitants 1.
Major Causes
Most Common in Adults:
- Pituitary adenomas (most frequent cause overall) 2
- Pituitary surgery (up to 90% after craniopharyngioma surgery) 1
- Cranial radiotherapy (deficiencies develop over years, up to 65% in brain tumor patients) 1
- Traumatic brain injury (increasingly recognized) 1
- Craniopharyngiomas (especially in younger patients, approximately 50% of central hypothyroidism cases) 1
Emerging Causes:
- Immune checkpoint inhibitors (drug-induced hypophysitis) 3
- Cerebral hemorrhage/stroke 4
- Autoimmune hypophysitis 3
Clinical Presentation
The key pitfall is that symptoms are often vague and nonspecific, leading to delayed diagnosis that can result in adrenal crisis and death 1. Look specifically for:
Central Adrenal Insufficiency (MOST DANGEROUS):
- Fatigue, weakness, weight loss
- Hypoglycemia (especially with stress)
- Can be fatal if untreated - requires high index of suspicion 1
- Unlike primary AI, typically NO hyperpigmentation or hyperkalemia
Central Hypothyroidism:
- Fatigue, cold intolerance, weight gain
- Associated with other pituitary deficiencies in ~50% of cases 1
Central Hypogonadism:
- Males: Low testosterone, decreased libido, erectile dysfunction, impaired spermatogenesis
- Premenopausal females: Amenorrhea, infertility, decreased libido 1
Growth Hormone Deficiency:
- Decreased muscle mass, increased adiposity
- Reduced quality of life and work capacity 1
Visual Field Defects:
- Suggest mass effect from pituitary tumor
Diagnostic Approach
Baseline Hormonal Assessment:
- Morning cortisol (if <3 μg/dL confirms AI; if >15 μg/dL excludes it; intermediate values need dynamic testing)
- Free T4 with TSH (low/normal TSH with low T4 indicates central hypothyroidism)
- LH, FSH, testosterone (males) or estradiol (females)
- IGF-1 for GH screening
- Prolactin
Dynamic Testing Required For:
- ACTH deficiency: Insulin tolerance test or cosyntropin stimulation test
- GH deficiency: Insulin tolerance test or GHRH-arginine test
- ADH deficiency: Water deprivation test
Neuroimaging:
- Brain MRI with pituitary protocol to identify structural causes (tumors, empty sella, stalk abnormalities)
Critical point: A high index of suspicion is essential because mild ACTH deficiency may only manifest during physiologic stress 1.
Management Priorities
Immediate Life-Saving Treatment:
If central adrenal insufficiency is suspected, start hydrocortisone replacement IMMEDIATELY before confirming diagnosis - delaying treatment can result in adrenal crisis and death 1.
Hormone Replacement Protocol:
Hydrocortisone (15-25 mg/day in divided doses for central AI)
- Must be replaced FIRST and ALWAYS
- Use non-supraphysiological doses 1
- Stress dosing required during illness/surgery
Levothyroxine (for central hypothyroidism)
- Start ONLY after cortisol replacement to avoid precipitating adrenal crisis
- Monitor free T4 levels (NOT TSH, which is unreliable in central disease)
Sex hormone replacement
- Males: Testosterone replacement
- Premenopausal females: Estrogen-progesterone replacement
- Requires individualized benefit-risk assessment based on age and comorbidities 3
Growth hormone replacement
Desmopressin (for diabetes insipidus if present)
Specialized Center Referral Indicated For:
- Enlarging pituitary tumors
- Pregnancy planning
- Pituitary apoplexy
- Multiple concomitant medications
- Persistent decreased quality of life 1
Morbidity and Mortality Impact
Hypopituitarism carries 5-10% excess mortality, with deaths primarily from malignancies, cardiovascular disease, and cerebrovascular disease 1. However, contemporary replacement protocols using appropriate doses may not adversely affect mortality 1.
Patients experience:
- Increased sick days and disability
- Lower employment rates (especially with GH deficiency)
- Higher healthcare costs
- Persistently reduced quality of life despite treatment 1
Monitoring Requirements
Lifelong monitoring is mandatory 5:
- Regular hormone level assessments
- Repeated pituitary function testing at intervals (deficiencies can evolve slowly after radiotherapy) 1
- Surveillance for hormone deficiency or excess symptoms
- Visual field testing if mass lesion present
The most critical error is failing to recognize and treat central adrenal insufficiency promptly, as this directly impacts mortality 1, 2.